

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 11, 2022

Endo International plc

(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction
of incorporation)

001-36326
(Commission File Number)

68-0683755
(IRS Employer
Identification No.)

**First Floor, Minerva House, Simmonscourt Road
Ballsbridge, Dublin 4, Ireland**
(Address of principal executive offices)

Not Applicable
(Zip Code)

Registrant's telephone number, including area code 011-353-1-268-2000

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Ordinary shares, nominal value \$0.0001 per share

Trading Symbol(s)
ENDP

Name of each exchange on which registered
The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

- Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On January 11, 2022, Endo International plc (the "Company") intends to make a presentation at the J.P. Morgan Healthcare Conference (the "Presentation"), a copy of which is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The Presentation will also be available on the Company's website at www.endo.com.

The information in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed by the Company with the U.S. Securities and Exchange Commission under the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Investor Presentation of Endo International plc dated as of January 11, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO INTERNATIONAL PLC

By: /s/ Matthew J. Maletta
Name: Matthew J. Maletta
Title: Executive Vice President,
Chief Legal Officer and Company Secretary

Dated: January 11, 2022



Forward Looking Statements

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "plan," "will," "may," "look forward," "intend," "guidance," "future," "potential" or similar expressions are forward-looking statements. All forward-looking statements in this presentation reflect Endo's current expectations of future events based on existing trends and information and represent Endo's judgment only as of the date of this presentation. Actual results may differ materially and adversely from current expectations based on a number of factors affecting Endo's businesses, including, among other things, the following: the outcome of our strategic review, contingency planning and any potential restructuring; the impact or results of any pending or future litigation, investigations, claims or actual or contingent liabilities, settlement discussions, negotiations or other adverse proceedings; our ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our ability to attract and retain personnel; our inability to maintain compliance with financial covenants and operating obligations which would expose us to potential events of default under our outstanding indebtedness; our ability to incur additional debt or equity financing for working capital, capital expenditures, business development, debt service requirements, acquisitions or corporate or other purposes; our ability to refinance our indebtedness; a significant reduction in our short-term or long-term revenues which could cause us to be unable to fund operations and liquidity needs or repay indebtedness. The occurrence or possibility of any such result has caused us to engage, and may result in further engagement in strategic reviews that ultimately may result in our pursuing one or more significant corporate transactions or other remedial measures, including on a preventative or proactive basis. The remedial measures could include a potential corporate reorganization, restructuring or bankruptcy filing involving all or a portion of our business, asset sales or other divestiture, cost-saving initiatives, corporate realignments or strategic partnerships. Some of these measures could take significant time to implement and others may require judicial or third-party approval. Any such actions may be complex, could entail significant costs and charges or could otherwise negatively impact shareholder value, and there can be no assurance that we will be able to accomplish any of these alternatives on terms acceptable to us, or at all, or that they will result in their intended benefits. Therefore, the reader is cautioned not to rely on these forward-looking statements. Endo expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo, as well as Endo's public periodic filings with the U.S. Securities and Exchange Commission and with securities regulators in Canada, including the discussion under the heading "Risk Factors" in Endo's most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the U.S. Securities and Exchange Commission.



Endo: A Diversified Specialty Pharmaceutical Company

Endo is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate team members collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them.

Our Vision

Helping everyone we serve live their best li

Our Mission

We develop and deliver life-enhancing products through focused execution.

Our Businesses

Branded Pharmaceuticals

Medical Therapeutics



Medical Aesthetics



Sterile Injectables



Generic Pharmaceuticals



Our Strategic Priorities

Expand & Enhance Our Portfolio

We are investing to build a more differentiated and durable portfolio that benefits our customers and creates sustainable long-term value.

Reinvent How We Work

We are embracing the future by accelerating new ways of working to better serve our customers, promote innovation, and improve productivity.

Be A Force For Good


We are committed to the adoption of more sustainable practices that positively impact our stakeholders, including the promotion of diversity & inclusion in all we do.



Our Branded Business Today

Medical Therapeutics + Medical Aesthetics

2021 Q3 YTD Revenue



¹ Represents percentage sales of overall reported sales

² 2021E amounts derived using revenue mid-points consistent with guidance provided on 11/4/2021

Medical Therapeutics



- ▶ Specialty products portfolio revenue CAGR of 14%; XIAFLEX® CAGR of 19% 2017–2021E²



- ▶ Broad portfolio of branded specialty products with urology and orthopedics focus
- ▶ Blazing new trails for non-surgical interventions

Medical Aesthetics



- ▶ Launched 1st commercial product QWO for cellulite in 2018
- ▶ Emerging non-surgical body contouring market has grown nearly 500% in the last 5 years
- ▶ Creating new category to tap into this opportunity



- ▶ Credentialed medical aesthetics sales & marketing team
- ▶ Scalable commercial infrastructure to support aesthetic product portfolio



XIAFLEX®: Maximizing for Long Term Value

Current On-market Indications



Peyronie's Disease

- ▶ Condition awareness campaign: specific request for XIAFLEX® for about 65-70% of the time by HCP
- ▶ Opportunity to further “medicalize” the situation



Dupuytren's Contracture

- ▶ New unbranded 2022 campaign featuring real patients
- ▶ Campaign intended to further increase condition awareness

Current Development Programs*

Indication	Pre-Clinical	Phase I/IB	Phase II/IIB	Phase III/IIIB	Filed	Updates
Plantar Fibromatosis	▶					▶ Phase II study initiated; last update expected in 4Q'22
Adhesive Capsulitis	▶					▶ Phase II study top line result expected in 3Q'22
Multiple	▶					▶ Programs in pre-clinical stage primarily in orthopedic care

*Multiple additional indications under review



QWO® in 2021: Building the foundation in Medical Aesthetics

>1,800 ACCOUNTS
Trained and Certified

>7.3 BILLION
Media Impressions

>220 Total media placements

- ✓ QWO has the highest top of mind awareness in the cellulite category*
- ✓ More patients are bringing up cellulite to their HCPs
- ✓ Majority of HCPs are aware of Endo Aesthetics as an aesthetic product manufacturer (aided)



*Unaided awareness. Based on Q3 2021 ATU survey of 200 aesthetic clinicians
7



QWO®: Focus on Creating Cornerstone Cellulite Treatment

Physician Education & Practice Integration



Ongoing Studies & Data Generation


224	CCH injected in grid pattern in non-obese subjects with mild to moderate cellulite of the thigh/buttocks	Final results expected in Q1'22
213	Extensively study the histopathologic effects of QWO in humans	Study complete, Final results under preparation
305	REAL world Phase 3b study for treatment of mild to moderate cellulite in thighs or buttocks of non-obese subjects	Study complete. Final results be presented at Dallas Cosm Surgery and Medicine Meeting (DCS 2022) in Mar-22
304	Three-year extension trial following Phase II cellulite subjects (follow-on to RELEASE-I and RELEASE-II studies)	Year 3 follow-up ongoing; Final results expected in Q1'22

Consumer Activation



Our Sterile Business Today

2021 Q3 YTD Revenue



- ▶ Revenue CAGR of 13% 2017–2021E²
- ▶ Vasostrict represents ~70% of Q3'21 YTD segment sales; potential for loss of exclusivity in early 2022



- ▶ Diversified manufacturing network anchored on 100 year plus legacy of quality and track record of reliability in our flagship Rochester, MI facility



- ▶ Expanding already robust complex injectable capabilities
- ▶ Established and proven commercial capabilities



- ▶ Products touch patients from birth to critical care
- ▶ Utilized by every U.S. healthcare system

¹ Represents percentage sales of overall reported sales

² 2021E amounts derived using revenue mid-points consistent with guidance provided on 11/4/2021



Sterile Injectables and Generics Pipeline Reflects Focus on More Durable and Differentiated Sterile Products


Sterile Injectable Product Continuum




Pipeline Highlights

- ▶ Launched 7 products in 2021 across the generic & sterile businesses; 1 launch in 2022 year-to-date
- ▶ >85% of projects in development are Sterile Injectables; ~ 2/3rd in ready-to-use or other differentiated products
- ▶ Sterile Injectable projects in development increased by >30%
- ▶ Remain highly active on external business development opportunities to further expand and enhance our pipeline

Q3'21 YTD Pending Filings – by Product Category




Q3'21 YTD R&D Pipeline – by Product Category



Our Generics Business Today

2021 Q3 YTD Revenue



¹ Represents percentage sales of overall reported sales

² 2021E amounts derived using revenue mid-points consistent with guidance provided on 11/4/2021



- ▶ Revenue decline at CAGR of 18% 2017–2021E²; Optimizing operations to improve efficiency



- ▶ Focus on differentiated generics and authorized generics driving significant value



- ▶ High-quality, lower cost manufacturing footprint & resilient supply chain



- ▶ High value launches including lubiprostone capsule and varenicline tablets in 2021
- ▶ Greater than 50% pipeline comprised of first-to-file/first-to-market opportunities,



Our Focus in 2022

Expand & Enhance Our Portfolio

Reinvent How We Work

Be A Force For Good

- ▶ Investing to enhance our portfolio and capabilities
 - Focused on Medical Therapeutics, Medical Aesthetics and Sterile Injectables
- ▶ Continue to evolve our ways of working
- ▶ Continue sustainability focus
- ▶ Maintain financial flexibility and disciplined capital allocation





Thank you

